BioVaxys Technology Corp. has successfully completed a sterile and bacteria-free test-run production of BVX-0918, the company’s bi-haptenized autologous ovarian cancer vaccine.    The complete manufacturing of BVX-0918 from a cancer patient’s ovarian tumor now validates the production protocols that had been in development over the past few months for the successful extraction of tumor cells, the cryo-packaging and cryo-preservation of tumor cells, identification of ovarian cancer ...